Trial Profile
A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients With de Novo Coronary Artery Lesions .( CREDIT II Trial )
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms CREDIT-II
- Sponsors JW Medical Systems
- 25 Apr 2023 Status changed from active, no longer recruiting to completed.
- 01 Mar 2017 Results of a pooled analysis assessing objective performance criteria in patients from two clinical studies (CREDIT-II and CREDIT-III; n=833), published in the Catheterization and Cardiovascular Interventions
- 11 Mar 2015 Status changed from recruiting to active, no longer recruiting, as reported in a Biosensors International Group media release.